Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Bancroft, E.K., Saya, S., Page, E.C., Myhill, K., Thomas, S., Pope, J., Chamberlain, A., Hart, R., Glover, W., Cook, J., et al. (2019). Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. Bju int, Vol.123 (2), pp. 284-292.  show abstract

Pathmanathan, A.U., McNair, H.A., Schmidt, M.A., Brand, D.H., Delacroix, L., Eccles, C.L., Gordon, A., Herbert, T., van As, N.J., Huddart, R.A., et al. (2019). Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy. Br j radiol, Vol.92 (1095), pp. 20180948-20180948.  show abstract

Pathmanathan, A.U., Schmidt, M.A., Brand, D.H., Kousi, E., As, N.J. & Tree, A.C. (2019). Improving fiducial and prostate capsule visualization for radiotherapy planning usingMRI. Journal of applied clinical medical physics, Vol.20 (3), pp. 27-36.

Brand, D.H., Parker, J.I., Dearnaley, D.P., Eeles, R., Huddart, R., Khoo, V., Murray, J., Suh, Y.-., Tree, A.C., van As, N., et al. (2019). Patterns of recurrence after prostate bed radiotherapy. Radiotherapy and oncology, .

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez-Iturriaga, A., Trippa, F., et al. (2019). Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. European urology, Vol.76 (6), pp. 732-739.

Brand, D.H., Tree, A.C., Hall, E. & van As, N. (2019). Optimal patient selection for stereotactic body radiotherapy – Authors' reply. The lancet oncology, Vol.20 (12), pp. e662-e662.

Hanna, G.G., Murray, L., Patel, R., Jain, S., Aitken, K.L., Franks, K.N., van As, N., Tree, A., Hatfield, P., Harrow, S., et al. (2018). UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clinical oncology, Vol.30 (1), pp. 5-14.

Binzel, K., Adelaja, A., Wright, C.L., Scharre, D., Zhang, J., Knopp, M.V., Teoh, E.J., Bottomley, D., Scarsbrook, A., Payne, H., et al. (2018). Abstracts of the 33rd International Austrian Winter Symposium. Ejnmmi research, Vol.8 (S1).

Pathmanathan, A.U., van As, N.J., Kerkmeijer, L.G., Christodouleas, J., Lawton, C.A., Vesprini, D., van der Heide, U.A., Frank, S.J., Nill, S., Oelfke, U., et al. (2018). Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A “Game Changer” for Prostate Treatment?. International journal of radiation oncology*biology*physics, Vol.100 (2), pp. 361-373.

Wedge, D.C., Gundem, G., Mitchell, T., Woodcock, D.J., Martincorena, I., Ghori, M., Zamora, J., Butler, A., Whitaker, H., Kote-Jarai, Z., et al. (2018). Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature genetics, Vol.50 (5), pp. 682-692.

Henderson, D.R., Murray, J.R., Gulliford, S.L., Tree, A.C., Harrington, K.J. & Van As, N.J. (2018). An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity. Clinical oncology, Vol.30 (9), pp. 539-547.

de Morrée, E.S., Vogelzang, N.J., Petrylak, D.P., Budnik, N., Wiechno, P.J., Sternberg, C.N., Doner, K., Bellmunt, J., Burke, J.M., Ochoa de Olza, M., et al. (2017). Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. Jama oncology, Vol.3 (1), pp. 68-68.

Bianchini, D., Lorente, D., Rescigno, P., Zafeiriou, Z., Psychopaida, E., O'Sullivan, H., Alaras, M., Kolinsky, M., Sumanasuriya, S., Sousa Fontes, M., et al. (2017). Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clinical genitourinary cancer, Vol.15 (5), pp. e801-e807.

Patrikidou, A., Uccello, M., Tree, A., Parker, C., Attard, G., Eeles, R., Khoo, V., van As, N., Huddart, R., Dearnaley, D., et al. (2017). Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. Clinical oncology, Vol.29 (10), pp. e174-e175.

Ost, P., Jereczek-Fossa, B.A., As, N.V., Zilli, T., Muacevic, A., Olivier, K., Henderson, D., Casamassima, F., Orecchia, R., Surgo, A., et al. (2016). Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. European urology, Vol.69 (1), pp. 9-12.

Henderson, D.R., Murray, J.R., Tree, A.C., Riley, U., Rosenfelder, N.A., Murray, D., Khoo, V.S. & van As, N.J. (2016). Targeted Antibiotic Prophylaxis for Transrectal Fiducial Marker Insertion for Prostate Radiotherapy. Clinical oncology, Vol.28 (3), pp. 226-227.

Henderson, D.R., de Souza, N.M., Thomas, K., Riches, S.F., Morgan, V.A., Sohaib, S.A., Dearnaley, D.P., Parker, C.C. & van As, N.J. (2016). Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. European urology, Vol.69 (6), pp. 1028-1033.

Henderson, D.R., de Souza, N.M., Parker, C.C. & van As, N.J. (2016). Reply from Authors re: Tillmann Loch, Pat Fox Fulgham Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow Eur Urol 2016;69:1034–6. European urology, Vol.69 (6), pp. 1037-1037.

McPartlin, A.J., Li, X.A., Kershaw, L.E., Heide, U., Kerkmeijer, L., Lawton, C., Mahmood, U., Pos, F., van As, N., van Herk, M., et al. (2016). MRI-guided prostate adaptive radiotherapy – A systematic review. Radiotherapy and oncology, Vol.119 (3), pp. 371-380.

Ost, P., Jereczek-Fossa, B.A., Van As, N., Zilli, T., Tree, A., Henderson, D., Orecchia, R., Casamassima, F., Surgo, A., Miralbell, R., et al. (2016). Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clinical oncology, Vol.28 (9), pp. e115-e120.

White, I.D., Wilson, J., Aslet, P., Baxter, A.B., Birtle, A., Challacombe, B., Coe, J., Grover, L., Payne, H., Russell, S., et al. (2015). Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int j clin pract, Vol.69 (1), pp. 106-123.  show abstract

Henderson, D., Murray, J., Tree, A., Riley, U., Murray, D. & van As, N. (2015). Fiducial Marker Insertion for Image-guided Radiotherapy for Prostate Cancer: What is the Infection Rate and can Targeted Antibiotic Prophylaxis Reduce this?. Clinical oncology, Vol.27 (3), pp. e5-e5.

Petrylak, D.P., Vogelzang, N.J., Budnik, N., Wiechno, P.J., Sternberg, C.N., Doner, K., Bellmunt, J., Burke, J.M., de Olza, M.O., Choudhury, A., et al. (2015). Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. The lancet oncology, Vol.16 (4), pp. 417-425.

Rosenfelder, N., Corbett, R., Long, M., Meehan, C., Duncan, N., Khoo, V. & Van As, N. (2015). Intensity modulated radiation therapy allows prostate and dose-escalated pelvic radical radiation therapy after renal transplantation. Pract radiat oncol, Vol.5 (3), pp. e207-e213.

Henderson, D.R., Tree, A.C. & van As, N.J. (2015). Stereotactic body radiotherapy for prostate cancer. Clin oncol (r coll radiol), Vol.27 (5), pp. 270-279.  show abstract

Aitken, K., Tree, A., Thomas, K., Nutting, C., Hawkins, M., Tait, D., Mandeville, H., Ahmed, M., Lalondrelle, S., Miah, A., et al. (2015). Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?. Clinical oncology, Vol.27 (7), pp. 411-419.

Dearman, C., van As, N., Crellin, A., Slevin, N. & Sharma, R.A. (2015). Surgery versus SABR for resectable non-small-cell lung cancer. The lancet oncology, Vol.16 (8), pp. e373-e374.

Hafeez, S., Horwich, A., Omar, O., Mohammed, K., Thompson, A., Kumar, P., Khoo, V., Van As, N., Eeles, R., Dearnaley, D., et al. (2015). Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. British journal of cancer, Vol.112 (10), pp. 1626-1635.

Tree, A., Ostler, P. & van As, N. (2014). New horizons and hurdles for UK radiotherapy: can prostate stereotactic body radiotherapy show the way?. Clin oncol (r coll radiol), Vol.26 (1), pp. 1-3.

Tree, A., Ostler, P., Hoskin, P., Dankulchai, P., Khoo, V. & van As, N. (2014). First UK Cohort of Prostate Stereotactic Body Radiotherapy (SBRT): Acute Toxicity and Early Prostate-specific Antigen (PSA) Outcomes. Clinical oncology, Vol.26 (2), pp. E7-E7.

Tree, A.C., Khoo, V.S., van As, N.J. & Partridge, M. (2014). Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?. Clin oncol (r coll radiol), Vol.26 (4), pp. 216-229.  show abstract

Tree, A., Siu, B., Townsend-Thorn, D., Murray, D., Riley, U., Khoo, V. & van As, N. (2014). The Incidence of Ciprofloxacin Resistance in Patients Undergoing Gold Seed Insertion for Image-guided Prostate Radiotherapy. Clinical oncology, Vol.26, pp. S8-S8.

Omlin, A., Pezaro, C.J., Zaidi, S., Lorente, D., Mukherji, D., Bianchini, D., Ferraldeschi, R., Sandhu, S., Dearnaley, D., Parker, C., et al. (2014). Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. Br j cancer, Vol.110 (1), pp. 267-268.

Bancroft, E.K., Page, E.C., Castro, E., Lilja, H., Vickers, A., Sjoberg, D., Assel, M., Foster, C.S., Mitchell, G., Drew, K., et al. (2014). Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European urology, Vol.66 (3), pp. 489-499.

Tree, A.C., Ostler, P., Hoskin, P., Dankulchai, P., Nariyangadu, P., Hughes, R.J., Wells, E., Taylor, H., Khoo, V.S. & van As, N.J., et al. (2014). Prostate stereotactic body radiotherapy—first UK experience. Clin oncol (r coll radiol), Vol.26 (12), pp. 757-761.  show abstract

Tree, A.C., Khoo, V.S., Eeles, R.A., Ahmed, M., Dearnaley, D.P., Hawkins, M.A., Huddart, R.A., Nutting, C.M., Ostler, P.J. & van As, N.J., et al. (2013). Stereotactic body radiotherapy for oligometastases. Lancet oncol, Vol.14 (1), pp. e28-e37.  show abstract

Tree, A., Jones, C., Sohaib, A., Khoo, V. & van As, N. (2013). Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?. Radiat oncol, Vol.8, p. 228.  show abstract

Omlin, A., Pezaro, C.J., Zaidi, S., Lorente, D., Mukherji, D., Bianchini, D., Ferraldeschi, R., Sandhu, S., Dearnaley, D., Parker, C., et al. (2013). Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br j cancer, Vol.109 (5), pp. 1079-1084.  show abstract

Eeles, R.A., Olama, A.A., Benlloch, S., Saunders, E.J., Leongamornlert, D.A., Tymrakiewicz, M., Ghoussaini, M., Luccarini, C., Dennis, J., Jugurnauth-Little, S., et al. (2013). Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat genet, Vol.45 (4), pp. 385-391e2.  show abstract

Tree, A., Wells, E., Khoo, V. & van As, N. (2013). Hypofractionated Radiotherapy with Cyberknife for Localised Prostate Cancer: Early Experience. Clinical oncology, Vol.25 (4), pp. E72-E73.

(2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. British journal of surgery, Vol.100 (8), pp. 1009-1014.

Beyond TME Collaborative, (2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br j surg, Vol.100 (8), pp. 1009-1014.  show abstract

(2013). Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. British journal of surgery, Vol.100 (8), pp. E1-E33.

Tree, A.C., Alexander, E.J., Van As, N.J., Dearnaley, D.P. & Khoo, V. (2013). Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?. Clin oncol (r coll radiol), Vol.25 (8), pp. 483-498.  show abstract

Amin Al Olama, A., Kote-Jarai, Z., Schumacher, F.R., Wiklund, F., Berndt, S.I., Benlloch, S., Giles, G.G., Severi, G., Neal, D.E., Hamdy, F.C., et al. (2013). A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum mol genet, Vol.22 (2), pp. 408-415.  show abstract

Ahmed, H.U., Akin, O., Coleman, J.A., Crane, S., Emberton, M., Goldenberg, L., Hricak, H., Kattan, M.W., Kurhanewicz, J., Moore, C.M., et al. (2012). Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. Bju international, Vol.109 (11), pp. 1636-1647.

Morgan, V.A., Riches, S.F., Thomas, K., Vanas, N., Parker, C., Giles, S. & Desouza, N.M. (2011). Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Brit j radiol, Vol.84 (997), pp. 31-37.  show abstract

Sham, J., Rosenfelder, N., Ashley, S., Lamb, C., Khoo, V., van As, N. & Dearnaley, D. (2011). Does Marker-based Prostate Radiotherapy Cause Worse Acute Toxicity?. Clin oncol-uk, Vol.23 (3), pp. S52-S52.

Rosenfelder, N., Corsini, L., Lamb, C., Aitken, A., van As, N., Burke, K., Bidmead, M., Khoo, V. & Brada, M. (2011). Can the Accuracy of a Stereotactic Frame be Achieved Using a Thermoplastic Shell?. Clin oncol-uk, Vol.23 (3), pp. S51-S51.

Rosenfelder, N., Lamb, C., Aitken, A., Bidmead, M., van As, N. & Khoo, V. (2011). On-line Image Verification for Prostate Radiotherapy - is Daily Correction Beneficial?. Clinical oncology, Vol.23 (3), pp. S51-S51.

Aitken, K., Lamb, C., Rosenfelder, N., Burke, K., Bidmead, M., Van As, N. & Khoo, V. (2011). Assessing the Stability of Prostate Fiducial Markers over a Course of Radiotherapy. Clinical oncology, Vol.23 (3), pp. S28-S28.

Macinnis, R.J., Antoniou, A.C., Eeles, R.A., Severi, G., Al Olama, A.A., McGuffog, L., Kote-Jarai, Z., Guy, M., O'Brien, L.T., Hall, A.L., et al. (2011). A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet epidemiol, Vol.35 (6), pp. 549-556.  show abstract

Kote-Jarai, Z., Olama, A.A., Giles, G.G., Severi, G., Schleutker, J., Weischer, M., Campa, D., Riboli, E., Key, T., Gronberg, H., et al. (2011). Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat genet, Vol.43 (8), pp. 785-791.  show abstract

Afaq, A., Koh, D.-., Padhani, A., van As, N. & Sohaib, S.A. (2011). Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. Bju int, Vol.108 (11), pp. 1716-1722.  show abstract

Okines, A.F., Hawkes, E.A., Rao, S., VAN As, N., Marsh, H., Riddell, A., Wilson, P.O., Osin, P. & Wotherspoon, A.C. (2010). Metastatic breast cancer presenting as a primary hindgut neuroendocrine tumour. Anticancer res, Vol.30 (7), pp. 3015-3018.  show abstract

Teoh, E.M., Dearnaley, D.P., Horwich, A., Van As, N., Riley, U. & Huddart, R.A. (2010). The efficacy of preventing neutropenic sepsis in patients with testicular germ cell tumours: results of two consecutive audits. Clin oncol (r coll radiol), Vol.22 (10), pp. 891-892.

Gilbert, D.C., Van As, N.J. & Huddart, R.A. (2009). Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors. Expert rev anticancer ther, Vol.9 (2), pp. 223-233.  show abstract

Ng, M.K., Van As, N., Thomas, K., Woode-Amissah, R., Horwich, A., Huddart, R., Khoo, V., Thompson, A., Dearnaley, D. & Parker, C., et al. (2009). Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. Bju int, Vol.103 (7), pp. 872-876.  show abstract

Eeles, R.A., Kote-Jarai, Z., Al Olama, A.A., Giles, G.G., Guy, M., Severi, G., Muir, K., Hopper, J.L., Henderson, B.E., Haiman, C.A., et al. (2009). Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat genet, Vol.41 (10), pp. 1116-1121.  show abstract

Al Olama, A.A., Kote-Jarai, Z., Giles, G.G., Guy, M., Morrison, J., Severi, G., Leongamornlert, D.A., Tymrakiewicz, M., Jhavar, S., Saunders, E., et al. (2009). Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat genet, Vol.41 (10), pp. 1058-1060.  show abstract

van As, N.J., de Souza, N.M., Riches, S.F., Morgan, V.A., Sohaib, S.A., Dearnaley, D.P. & Parker, C.C. (2009). A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur urol, Vol.56 (6), pp. 981-987.  show abstract

Gilbert, D.C., Vanas, N.J., Beesley, S., Bloomfield, D., Money-Kyrle, J., Norman, A., Dearnaley, D., Horwich, A. & Huddart, R.A. (2009). Treating IIA/B seminoma with combination carboplatin and radiotherapy. J clin oncol, Vol.27 (12), pp. 2101-2102.

Van As, N., Charles-Edwards, E., Jackson, A., Jhavar, S., Reinsberg, S., Desouza, N., Dearnaley, D., Bailey, M., Thompson, A., Christmas, T., et al. (2008). Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br j radiol, Vol.81 (966), pp. 456-462.  show abstract

Desouza, N.M., Riches, S.F., VanAs, N.J., Morgan, V.A., Ashley, S.A., Fisher, C., Payne, G.S. & Parker, C. (2008). Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin radiol, Vol.63 (7), pp. 774-782.  show abstract

van As, N.J., Norman, A.R., Thomas, K., Khoo, V.S., Thompson, A., Huddart, R.A., Horwich, A., Dearnaley, D.P. & Parker, C.C. (2008). Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur urol, Vol.54 (6), pp. 1297-1305.  show abstract

van As, N.J., Gilbert, D.C., Money-Kyrle, J., Bloomfield, D., Beesley, S., Dearnaley, D.P., Horwich, A. & Huddart, R.A. (2008). Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br j cancer, Vol.98 (12), pp. 1894-1902.  show abstract

van As, N., Parker, C., Desouza, N., Thompson, A., Khoo, V., Dearnaley, D. & Sohaib, S.A. (2007). Magnetic resonance imaging is the modality of choice for accurate assessment of prostate volume. Clin oncol-uk, Vol.19 (4), pp. S4-S4.

van As, N., Charles-Edwards, E., Jackson, A., Jhavar, S., Reinsberg, S., deSouza, N., Dearnaley, D., Baileys, M., Thompson, A., Christmas, T., et al. (2007). Correlation of diffusion-weighted MRI (DWMRI) with whole mount radical prostatectomy specimen. Clin oncol-uk, Vol.19 (4), pp. S4-S4.

van As, N.J. & Parker, C.C. (2007). Active surveillance with selective radical treatment for localized prostate cancer. Cancer j, Vol.13 (5), pp. 289-294.  show abstract

van As, N., Jackson, A., Sohaib, S., South, C., Charles-Edwards, E., Reinsberg, S., Leach, M. & Dearnaley, D. (2005). Prostate and pelvis radiotherapy using IMRT and ultra small superparamagnetic nano-particles to optimise dose to involved lymph nodes. Ejc suppl, Vol.3 (2), pp. 399-400.

Van As, N., Calonje, E., Andrews, V., Griffiths, W.A. & Leslie, M.D. (2005). Complete resolution of anal cancer after chemotherapy for acute myeloid leukaemia. Lancet oncology, Vol.6 (11), pp. 908-909.

Wedlake, L., Shaw, C., McNair, H., Lalji, A., Mohammed, K., Klopper, T., Allan, L., Tait, D., Hawkins, M., Somaiah, N., et al. Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. The american journal of clinical nutrition, , pp. ajcn150565-ajcn150565.

Dearnaley, D., reis ferreira, M., khan, A., truelove, L., gao, A., parker, C., huddart, R., eeles, R., khoo, V. & van as, N., et al. A phase I/II dose escalation study of the use of intensity modulated radiotherapy (IMRT) to treat the prostate and pelvic nodes in patients with prostate cancer. International journal of radiation oncology • biology • physics, .

Henderson, D., Tree, A., Harrington, K. & van As, N. Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer. Medicines, Vol.5 (2), pp. 32-32.

Hall, E., Brand, D., Tree, A., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S., Jain, S., et al. Intensity Modulated Fractionated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Results From a Randomised Open-label Phase III Non-inferiority Trial. The lancet oncology, .


Book Chapters

van As, (2012). Principles of Imaging for Radiotherapy. In Sibtain, A., Morgan, A. & MacDougall, N. (Eds.), Physics for Clinical Oncology. (p. 263). Oxford University Press, ISBN: 9780199573356.

van As, (2011). Prostate Motion: Implications and Management Strategies. In Ponsky, L.E., Fuller, D.B. & Meier, R.M. (Eds.), Robotic Radiosurgery Treating Prostate Cancer and Related Genitourinary Applications. (p. 265). Springer, ISBN: 9783642114953.

van As, (2007). Expectant Management of Early Prostate Cancer. In Nargund, V.H., Raghavan, D. & Sandler, H.M. (Eds.), Urological Oncology. (p. 634). Springer, ISBN: 9781846283871.

van As, & huddart, R. (2007). Radiotherapy for bone pain. In Davies, A. (Ed.), Cancer-related Bone Pain. (p. 118). Oxford University Press, USA, ISBN: 9780199215737.


Conferences

Morrison, K., Naismith, O. & van As, N. (2019). Variability Analysis of Clinical Target Volume Outlining for Prostate Stereotactic Body Radiotherapy within the Multicentre PACE Trial, Clinical Oncology, Vol.31 (2), p.e23.

Teoh, E.J., Bottomley, D.M., Scarsbrook, A., Payne, H., Afaq, A., Bomanji, J., Van As, N., Chua, S., Hoskin, P., Chambers, A., et al. (2018). The FALCON trial: Impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer., Journal of Clinical Oncology, Vol.36 (6_suppl), p.165.

Morrison, K., Tree, A., Khoo, V. & Van As, N.J. (2018). The PACE trial: International randomised study of laparoscopic prostatectomy vs. stereotactic body radiotherapy (SBRT) and standard radiotherapy vs. SBRT for early stage organ-confined prostate cancer., Journal of Clinical Oncology, Vol.36 (6_suppl), p.TPS153.

Pathmanathan, A., Mitchell, A., Thomas, K., Henderson, D., Nill, S., Oelfke, U., Huddart, R., Van As, N. & Tree, A. (2017). PO-0828: Stereotactic body radiotherapy (SBRT) for localised prostate cancer on the MR-Linac, Radiotherapy and Oncology, Vol.123, p.S445.

Augustin, Y., Chaw, C., Van As, N. & Aitken, K. (2017). EP-1273: Stereotactic body radiation therapy (SBRT) for pelvic re-irradiation, Radiotherapy and Oncology, Vol.123, p.S684.

Chaw, C.L., VanAs, N.J. & Khoo, V.S. (2017). EP-1549: Cyberknife Iris based versus InCise based plans for 20 cases of prostate oligonodal metastases, Radiotherapy and Oncology, Vol.123, p.S834.

Patel, R., Williams, T., Payne, J., Eaton, D.J., Tsang, Y., Ostler, P. & Van As, N. (2016). EP-1945: Plan submission comparison for commissioning of spinal and nodal SABR for oligometastases, Radiotherapy and Oncology, Vol.119, pp.S922-S923.

Hanna, G.G., Patel, R., Aitken, K., Jain, S., Franks, K., Van As, N., Tree, A., Harrow, S., Eaton, D.J., McDonald, F., et al. (2016). EP-1937: UK stereotactic ablative radiotherapy trials normal tissue dose constraints tolerance consensus, Radiotherapy and Oncology, Vol.119, p.S919.

Bianchini, D., Lorente Estelles, D., Rescigno, P., 'O Sullivan, H., Kolinsky, M.P., Sumanasuriya, S., Zafeiriou, Z., Mehra, N., Jayaram, A., Mateo, J., et al. (2016). Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis., Journal of Clinical Oncology, Vol.34 (2_suppl), p.280.

Henderson, D.R., Tree, A., Taylor, H., Khoo, V. & Van As, N.J. (2015). Oligometastatic prostate cancer: An evaluation of stereotactic body radiotherapy (SBRT) as an alternative to palliative androgen deprivation therapy., Journal of Clinical Oncology, Vol.33 (7_suppl), p.229.

Henderson, D.R., Tree, A. & van As, N. (2015). Stereotactic Body Radiation Therapy Planning for Localized Prostate Cancer in the PACE Phase 3 Trial: Can This Be Done Without Fused Planning MRI?, International Journal of Radiation Oncology*Biology*Physics, Vol.93 (3), p.E202.

Henderson, D.R., DeSouza, N.M., Thomas, K., Morgan, V.A., Riches, S.F., Sohaib, S.A., Dearnaley, D.P., Parker, C. & Van As, N.J. (2015). Nine-year follow-up for a study of diffusion-weighted MRI in a prospective active surveillance cohort for prostate cancer., Journal of Clinical Oncology, Vol.33 (15_suppl), p.5043.

Tree, A., Aluwini, S., Bryant, H., Hall, E., Incrocci, L., Kaplan, I., Ostler, P., Sanda, M., Thompson, A. & van As, N., et al. (2013). Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.87 (2), p.S365.

Tree, A.C., Khoo, V.S. & Van As, N.J. (2013). Salvage stereotactic body radiotherapy in radio-recurrent prostate cancer - what dose is feasible?, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S690.

Dudderidge, T.J., Ramsden, A., Kumar, P., Rosenfelder, N., Van As, N. & Ogden, C. (2012). Oncological outcomes from salvage radiotherapy for biochemical recurrence after robotic assisted laparoscopic prostatectomy (RALP), BJU INTERNATIONAL, Vol.109, p.5.

Burke, K., Lamb, C., Rosenfelder, N., Bidmead, M., van As, N. & Khoo, V. (2011). 1270 poster DOSIMETRIC IMPLICATIONS OF UNCORRECTED ROTATION OF THE PROSTATE DURING EXTERNAL BEAM RADIOTHERAPY, Radiotherapy and Oncology, Vol.99, pp.S473-S474.

Schick, U., Rosenfelder, N., Lamb, C., Thomas, K., Aitken, A., van As, N. & Khoo, V. (2011). 1257 poster RESIDUAL ERRORS IMMEDIATELY AFTER ON-LINE CORRECTION: PROSTATE OR PATIENT MOVEMENT?, Radiotherapy and Oncology, Vol.99, p.S469.

Sham, J., Rosenfelder, N., Ashley, S., Lamb, C., van As, N. & Khoo, V. (2011). 1011 poster DOES MARKER-BASED PROSTATE RADIOTHERAPY CAUSE WORSE ACUTE TOXICITY?, Radiotherapy and Oncology, Vol.99, p.S380.

Aitken, K., Lamb, C., Rosenfelder, N., Burke, K., Bidmead, M., van As, N. & Khoo, V. (2011). 1026 poster INTRA-PROSTATIC FIDUCIAL MARKER STABILITY; SUB-MM AVERAGE MARKER DISPLACEMENT THROUGHOUT TREATMENT, Radiotherapy and Oncology, Vol.99, p.S384.

Jani, Z., Rosenfelder, N., Humphreys, M., McNair, H., Burke, K., Berstein, D., van As, N. & Khoo, V. (2011). 1260 poster THE INFLUENCE OF RECTAL FILLING ON RECTAL DISPLACEMENT AND ITS IMPACT ON DOSIMETRY WITHIN THE PTV, Radiotherapy and Oncology, Vol.99, p.S470.

van As, N., Rosenfelder, N., Lamb, C., Schick, U., Burke, K., Bidmead, M., Aitken, A. & Khoo, V. (2011). 1027 poster IS DAILY ONLINE CORRECTION BENEFICIAL FOR PROSTATE RADIOTHERAPY?, Radiotherapy and Oncology, Vol.99, p.S384.

Morgan, S., Thomas, K., van As, N., Huddart, R., Horwich, A., Dearnaley, D. & Parker, C. (2010). ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER: DEVELOPMENT OF A NOMOGRAM TO PREDICT THE PROBABILITY OF DEFERRED RADICAL TREATMENT, RADIOTHERAPY AND ONCOLOGY, Vol.96, p.S44.

Rosenfelder, N., Aitken, A., van As, N. & Khoo, V. (2010). CONE-BEAM CT VERIFICATION FOR PROSTATE RADIOTHERAPY: MANUAL VERSUS AUTOMATIC REGISTRATION, RADIOTHERAPY AND ONCOLOGY, Vol.96, pp.S398-S399.

Aitken, A., Burke, K., Rosenfelder, N., Lamb, C., Hawkins, M., Nalder, C., van As, N., Bidmead, M. & Khoo, V. (2009). IMAGE REGISTRATION USING 6 VERSUS 4 DEGREES OF FREEDOM FOR VERIFICATION OF RADICAL PROSTATE RADIOTHERAPY, Radiotherapy and Oncology, Vol.92, p.S186.

McVey, G.P., Van As, N., Thomas, K., Margaret, B., South, C., Chris, P., Khoo, V., Huddart, R., Horwich, A. & Dearnaley, D., et al. (2009). Intensity Modulated Radiotherapy (IMRT) Can Safely Deliver 60 Gy to the Pelvic Lymph Node Regions in Patients with Prostate Cancer: Report of a Phase I Dose Escalation Study, Presented at 51st Annual Meeting of the American-Society-for-Radiation-Oncology, Chicago, IL. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.75 (3), p.S48.

van As, N., Norman, A.R., Khoo, V.S., Thompson, A., Huddart, R.A., Horwich, A., Dearnaley, D.P. & Parker, C.C. (2007). Avoiding overtreatment of prostate cancer: optimising patient selection for active surveillance, Presented at 14th European Cancer Conference (ECCO 14), Barcelona, SPAIN. EJC SUPPLEMENTS, Vol.5 (4), p.280.

van As, N., Gilbert, D.C., Dearnaley, D.P., Horwich, A., Beesley, S., Money-Kyrle, J., Bloomfield, D. & Huddart, R.A. (2007). Evidence based guidelines for the follow-up of testicular cancer, Presented at 14th European Cancer Conference (ECCO 14), Barcelona, SPAIN. EJC SUPPLEMENTS, Vol.5 (4), p.298.

van As, N.J., Ng, M.K., Norman, A.R., Huddart, R., Dearnaley, D., Horwich, A., Thompson, A., Woode-Amissah, R., Khoo, V. & Parker, C., et al. (2007). The prognostic value of PSA derivatives in favourable risk localised prostate cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol.25 (18).

Foo, K., Coffey, J., Mangar, S., van As, N., Khoo, V., Sohaib, A., Huddart, R., Horwich, A. & Dearnaley, D. (2006). Optimising radiotherapy for seminoma using fields based on surgical templates for retroperitoneal lymph node dissection, Presented at Conference of the Spanish-Portuguese-and -Latin-American-Association, Leipzig, GERMANY. RADIOTHERAPY AND ONCOLOGY, Vol.81, pp.S531-S532.

In this section

Research overview Publications